Article

A randomized controlled trial of a 12‐month course of recombinant human interferon‐α in chronic delta (type D) hepatitis: A multicenter Italian study

Hepatology (Impact Factor: 11.19). 06/1991; 13(6):1052 - 1056. DOI: 10.1002/hep.1840130608

ABSTRACT To determine whether long-term therapy with recombinant interferon- can improve the course of chronic delta hepatitis, 61 Italian patients with this disease were randomly assigned to receive either interferon--2b three times a week (5 MU/m2 for 4 mo and then 3 MU/m2 for another 8 mo) or no treatment. At the end of the 12-mo study, all patients were followed-up for 12 additional months. Normalization or decrease of more than 50% from baseline of serum ALT levels occurred in 42% of treated patients the fourth month of therapy, 26% the twelfth month and 3% the twenty-fourth month vs. 7%, 7% and 0%, respectively, in the control group. However, relapses occurred in 7 of 8 (87.5%) responders 1 to 10 mo (mean = 3.5 mo) after cessation of therapy.Liver biopsies were carried out at baseline and during the twelfth month of treatment. Histological improvement, mostly caused by decrease of portal inflammation, was observed in 57% of treated and 36% of untreated patients. Measures of antiviral activity (serum hepatitis delta virus RNA and intrahepatic hepatitis delta antigen) showed similar levels in treated and control patients. In treated patients the percentage of patients who were negative for HDV RNA never exceeded that of baseline.Although interferon- in the dosage given in this study had no antiviral effect on patients with chronic hepatitis D, it reduced hepatic inflammation as measured by ALT levels. Whether a longer duration or reinstitution of interferon- therapy would achieve longterm control of ALT levels and prevent chronic liver damage is not known. (HEPATOLOGY 1991;13:1052–1056.)

0 Followers
 · 
40 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Akute und chronische Virushepatitiden gehören nach wie vor zu den großen Volkskrankheiten. Sie sind verantwortlich für einen erheblichen Teil der Fälle von Leberzirrhose, stellen eine häufige Indikation für die Lebertransplantation dar und sind die wichtigsten Risikofaktoren für die Entstehung hepatozellulärer Karzinome. In den letzten 15 Jahren hat sich die Interferontherapie der Hepatitiden als Standardtherapie etabliert. Hierzu trug der rasche Erkenntniszuwachs in der Hepatologie, aber auch die Verfügbarkeit rekombinanter, stabiler Interferone bei. Die Interferontherapie ist als eine Therapie mit immunologisch aktiven Substanzen nicht ohne Nebenwirkungen; auch ist sie in der Durchführung relativ aufwendig und zudem teuer. Daher war sie in den ersten Jahren ausschließlich an hepatologisch orientierten Zentrumskliniken angesiedelt. Dies hat sich mit zunehmender Erfahrung und durch besser fundierte Therapieschemata grundlegend geändert. Heute ist die Behandlung chronischer Hepatitiden mit Interferon eine Therapieform, mit der jeder Internist in Berührung kommen kann. Gleichzeitig ist eine große Fülle von Daten und Ergebnissen zur Interferontherapie publiziert worden und hat auf die Entwicklung der Behandlungsschemata Einfluß genommen. Die Konzepte der Therapie sind dabei auch heute noch teilweise im Fluß. Die vorliegende Übersicht versucht, einen Überblick über den gegenwärtigen Stand der Diskussion über Möglichkeiten und Grenzen der Interferontherapie bei viraler Hepatitis zu vermitteln.
    Der Internist 38(12):1191-1203. DOI:10.1007/s001080050131
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial. Two patients were withdrawn: one developed hemolytic anemia, and the other intractable itching. At the end of treatment HD viremia was reduced in one patient, had cleared in another, and was unchanged in the remaining five patients. None of the patients decreased their alanine transferase (ALT) levels by more than 50%. At the doses given in this study. Ribavirin did not show significant antiviral effects in chronic hepatitis D, and was not effective in reducing the biochemical markers of liver inflammation and necrosis.
    Liver International 07/1994; 14(3):154-7. DOI:10.1111/j.1600-0676.1994.tb00065.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic viral hepatitis caused by hepatitis B, C or D may lead to cirrhosis, hepatocellular failure and hepatocellular carcinoma. The morbidity of these diseases has necessitated a prolonged search for effective therapy. Interferon-alpha has been studied widely, and remains the mainstay of treatment. Therapy for hepatitis B has now become possible with the demonstration that alpha-interferons inhibit hepatitis B virus (HBV) replication and that prolonged therapy can lead to a remission in disease. A number of other cytokines, including thymosin, are being evaluated. Currently used nucleoside analogues and anti-retroviral therapies used in human immunodeficiency virus infection have not proven useful in chronic hepatitis B. There are a number of new experimental nucleoside analogues with activity against HBV. Unfortunately, fialuridine has been associated with severe mitochondrial damage and hepatotoxicity. Other stereoisomers may be more active and less toxic, but the potential danger of these drugs indicates that large scale clinical trials should proceed cautiously. Experimental test systems for the preliminary investigation of antiviral compounds in hepatitis B and C will be required. Antisense oligodeoxyribonucleotides may inhibit the expression of the HBV genes. The natural history of hepatitis C is uncertain. Therapeutic trials of interferon-alpha indicated that a proportion of patients may respond to treatment with this agent. There is most information about 3 mU t.i.w. administered for 6 months. It is not yet clear whether this dose is optimal. Multivariate analysis of several pretreatment parameters indicate that patients without cirrhosis are more responsive to interferon. The influence of genotypes of hepatitis C is the subject of considerable interest at present. Patients with diverse circulating quasispecies may be less responsive to therapy than those with a single major species. Improved responses have been observed in patients with lower levels of circulating hepatitis C virus RNA.
    Pharmacology [?] Therapeutics 02/1995; 65(1):47-73. DOI:10.1016/0163-7258(94)00056-9